Valuation: Royalty Pharma plc

Market Cap 25.35B 22.69B 21.15B 19.19B 36.19B 2,423B 36.42B 254B 99.52B 1,250B 95.22B 93.11B 4,024B P/E 2026 *
23.2x
P/E 2027 * 16.4x
Enterprise Value 34.34B 30.74B 28.66B 26B 49.03B 3,283B 49.34B 344B 135B 1,694B 129B 126B 5,452B EV / Sales 2026 *
9.8x
EV / Sales 2027 * 9.02x
Free-Float
72.42%
Yield 2026 *
1.77%
Yield 2027 * 1.9%
1 day+1.49%
1 week+1.98%
Current month-0.99%
1 month-2.15%
3 months+2.36%
6 months+19.31%
Current year+49.53%
1 week 55.13
Extreme 55.13
57.92
1 month 55.13
Extreme 55.13
59.55
Current year 38.29
Extreme 38.29
64.38
1 year 35.23
Extreme 35.23
64.38
3 years 24.05
Extreme 24.05
64.38
5 years 24.05
Extreme 24.05
64.38
10 years 24.05
Extreme 24.05
64.38
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Executive/Senior Manager

-4,126 0.0009%
9/30/26 Free

Director

642 0.0001%
9/28/26 Sell

Executive/Senior Manager

-4,126 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+1.49%+1.98%+63.04%+113.21% 25.35B
+0.28%+3.46%+44.33%+93.71% 1,051B
+0.88%+4.27%+38.15%+68.70% 630B
+1.68%+5.78%+22.07%+89.56% 489B
-0.10%+4.24%+69.72%+40.41% 359B
+0.61%+4.14%+24.05%+41.70% 344B
+0.72%+3.11%+14.29%+33.76% 272B
+0.23%+1.31%-5.91%+9.89% 246B
+0.65%+3.62%+42.81%+46.50% 224B
-0.49%+4.01%+27.26%+95.97% 187B
Average +0.41%+2.53%+33.98%+63.34% 382.91B
Weighted average by Cap. +0.38%+2.91%+34.86%+67.21%

Financials

2026 *2027 *
Net sales 3.5B 3.14B 2.92B 2.65B 5B 335B 5.04B 35.15B 13.76B 173B 13.17B 12.87B 556B 3.82B 3.42B 3.19B 2.89B 5.45B 365B 5.49B 38.3B 14.99B 188B 14.35B 14.03B 606B
Net income 1.47B 1.31B 1.22B 1.11B 2.09B 140B 2.1B 14.69B 5.75B 72.27B 5.5B 5.38B 233B 1.77B 1.59B 1.48B 1.34B 2.53B 169B 2.55B 17.77B 6.96B 87.4B 6.66B 6.51B 281B
Net Debt 8.99B 8.05B 7.51B 6.81B 12.84B 860B 12.92B 90.19B 35.31B 444B 33.78B 33.03B 1,428B 9.1B 8.15B 7.59B 6.89B 12.99B 870B 13.07B 91.25B 35.72B 449B 34.18B 33.42B 1,444B
Projected Income Statement - Annual - Royalty Pharma plc
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
26-10-12 US$57.78 +1.49% 2,174,431
26-10-09 US$56.93 +1.28% 2,881,985
26-10-08 US$56.21 -0.97% 2,847,237
26-10-07 US$56.76 +0.57% 3,671,203
26-10-06 US$56.44 -0.39% 2,434,244
Trader
Investor
Global
Quality
ESG MSCI
AAA
Ratings Surperformance© - Royalty Pharma plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
56.93USD
Average target price
65.38USD
Spread / Average Target
+14.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Royalty Pharma plc
  1. Stock Market
  2. Stocks
  3. RPRX Stock